Tesla TSLA -1.04% ▼ CEO Elon Musk has filed a motion to dismiss a civil lawsuit brought by the U.S. Securities and Exchange Commission (SEC). The suit accuses him of waiting too long in 2022 to reveal his large stake in Twitter, now called X. The SEC says Musk broke disclosure rules by missing the 10-day filing deadline required when investors cross a 5% ownership threshold.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

SEC Alleges Musk Delayed Filing to Benefit

According to the SEC, Musk should have disclosed his stake by March 24, 2022, but instead revealed his position 11 days late on April 4. By then, he had quietly built a 9.2% stake worth more than $500 million at artificially suppressed prices.

Regulators argue this allowed Musk to keep buying Twitter shares at lower prices, leaving other investors at a disadvantage. The agency wants Musk to pay fines and give up any profits tied to the delay.

Musk Argues He Acted in Good Faith

Musk’s lawyers said that he stopped buying Twitter shares once his wealth manager checked with securities lawyers about filing rules. They argue Musk disclosed his position the very next business day and did not act recklessly or with bad intent.

His team also accused the SEC of unfairly targeting him because of his “protected criticism of government overreach.”

Musk Faces Deadline to Respond

Musk faced a court deadline this week to respond to the SEC complaint. His lawyers said the case should never have been filed, pointing out that the issue centers on a single delayed form that Musk corrected more than three years ago. They added there is no ongoing violation.

While Tesla is not involved in the case, Musk’s legal troubles can still affect investor confidence in his companies.

Is Tesla a Buy, Sell, or Hold? 

On Wall Street, analysts have maintained a cautious stance on Tesla stock. According to TipRanks, TSLA stock has received a Hold consensus rating, with 14 Buys, 15 Holds, and eight Sells assigned in the last three months. The average stock price target for Tesla is $307.90, suggesting a potential downside of 11.01% from the current level.

See more TSLA analyst ratings

Disclaimer & DisclosureReport an Issue

Tech giant Microsoft MSFT +0.57% ▲ has begun testing its in-house artificial intelligence (AI) models that will compete directly with partner OpenAI while also reducing reliance on the ChatGPT maker. The company has launched two customer-focused AI models under its MAI (Microsoft Artificial Intelligence) brand, named MAI-Voice-1 and MAI-1-preview. The announcement was made by Microsoft AI CEO Mustafa Suleyman in an X post yesterday.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The MAI-Voice-1 model is a speech-generation system that can produce an audio of about a minute in under one second. Meanwhile, the MAI-1-preview model is a text-based system designed to follow instructions and reply to routine questions in a conversational manner.

Here’s How Microsoft Seeks to Compete in AI

The MAI-1-preview is the company’s first language model that is trained completely in-house, from start to finish, without any help from OpenAI. The model was trained on about 15,000 Nvidia NVDA -0.79% ▼ H100 GPUs (Graphics Processing Units) and is now available for public testing on the LMArena platform. The model is considered highly cost-effective compared to rivals such as xAI’s Grok, which was trained on more than 100,000 GPUs.

Notably, Microsoft has already integrated MAI-Voice-1 into several products, such as Copilot Daily, where the model narrates daily news stories and hosts podcasts. It is also available for testing on Microsoft’s Copilot Labs. With these models, Microsoft is expanding its focus to consumer-oriented AI, aiming to create helpful, expressive, and accessible AI companions for everyday use.

To date, Microsoft has invested up to $13 billion in OpenAI and has been largely dependent on the startup for AI models. However, recent tensions between the two parties, related to OpenAI’s transformation to a public entity, Microsoft’s equity terms, and cloud exclusivity, have prompted Microsoft to strengthen its own AI capabilities. Suleyman has stressed the importance of developing “in-house expertise to create the strongest models in the world.”

Is MSFT Stock a Buy, Hold, or Sell?

On TipRanks, MSFT stock has a Strong Buy consensus rating based on 33 Buys and one Hold rating. The average Microsoft price target of $624.08 implies 22.5% upside potential from current levels. Year-to-date, MSFT stock has gained 21.6%.

See more MSFT analyst ratings

Disclaimer & DisclosureReport an Issue

UnitedHealth Group UNH -0.52% ▼ seems to be caught in one controversy after another, with shares already down more than 40% year-to-date. Now, the largest U.S. health insurer is facing fresh pressure from lawmakers over billions of dollars in loans it issued to healthcare providers after last year’s cyberattack.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Senators Elizabeth Warren (D–Mass.) and Ron Wyden (D–Ore.) have asked the company to explain its repayment practices, following reports that some providers were pushed to return funds on short notice.

Fallout From UnitedHealth’s Cyberattack

In February 2024, UnitedHealth’s Change Healthcare unit — a major processor of medical claims — was hit by a cyberattack that crippled billing systems across the U.S. To ease the cash crunch, UnitedHealth set up a Temporary Funding Assistance Program, issuing more than $9 billion in interest-free loans to hospitals, doctors, and clinics.

Now, more than a year later, the repayment process has come under fire. Reports suggest UnitedHealth pressed many providers to repay loans within weeks or risk losing reimbursement for their claims. This has raised concerns in Washington, where lawmakers say providers were left in financial trouble by a crisis they did not cause.

Lawmakers Question Repayment Tactics

In a letter to UnitedHealth CEO Stephen Hemsley and Optum Financial CEO Dhivya Suryadevara, Senators Elizabeth Warren and Ron Wyden criticized what they called “hardball tactics” in the company’s loan collection efforts. They asked UnitedHealth to provide details on:

• The total number of loans issued
• Repayment terms
• Written agreements with providers
• Options available for providers unable to repay within 45 days
• Whether third-party debt collectors are involved

Lawmakers have set a deadline of September 12, 2025, for UnitedHealth to reply.

In response, a Change Healthcare spokesperson said the company has worked with “thousands of providers” to agree on repayment plans and noted that most have already met their obligations.

More Troubles Pile Up for UnitedHealth

The loan dispute adds to UnitedHealth’s growing list of regulatory problems. The Department of Justice (DOJ) is already investigating the company’s Medicare operations. Just recently, the DOJ has expanded its criminal investigation beyond Medicare Advantage billing to include other business practices. At the same time, the FTC is pressing forward with a lawsuit accusing UnitedHealth’s Optum Rx, along with other large PBMs (pharmacy benefit managers), of inflating insulin prices.

Earlier this month, Senators Warren and Wyden also opened a separate probe into whether UnitedHealth paid nursing homes bonuses for cutting down on hospital transfers.

What Is the Future of UNH Stock? 

Turning to Wall Street, UNH stock has a Strong Buy consensus rating based on 17 Buys, two Holds, and one Sell assigned in the last three months. At $314.95, the average UnitedHealth stock price target implies a 4.19% upside potential.

See more UNH analyst ratings

Disclaimer & DisclosureReport an Issue

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Thursday, August 28, 2025, according to the funds’ daily disclosures. The moves highlight ARK’s ongoing confidence in the biotechnology sector, with fresh buying in gene-editing player Intellia Therapeutics NTLA +1.58% ▲ . At the same time, ARK trimmed its positions in TV streaming giant Roku ROKU +1.41% ▲ and online sports betting operator DraftKings DKNG +0.90% ▲ .

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Wood Extends Selling in Roku and DraftKings

The biggest move of the day came from the sale of Roku shares. ARK’s flagship ARK Innovation ETF ARKK +0.73% ▲ offloaded 55,624 shares, worth about $5.35 million, extending a selling streak that has lasted throughout the past week. The repeated trimming suggests ARK may be pulling back from the streaming device company after years of heavy exposure.

ARK also cut its stake in DraftKings, selling 54,679 shares across three funds — the ARKK, ARK Next Generation Internet ETF ARKW +1.39% ▲ , and ARK Fintech Innovation ETF ARKF +1.37% ▲ — for about $2.61 million. The sale continues a pattern of reduced exposure this week, pointing to a possible reallocation away from digital sports betting and gaming.

In terms of performance, Roku and DraftKings shares have gained 31.2% and 29.7% year-to-date, respectively.

Wood Boosts Biotech Bet with Intellia Purchase

Meanwhile, ARK leaned into biotech with its largest purchase of the day: Intellia Therapeutics. The ARKK ETF added 349,930 Intellia shares worth about $4.0 million.

Intellia, a leader in gene-editing technology, has been a consistent buy for ARK in recent weeks, signaling growing conviction in its long-term prospects. The stock has gained over 56% in the past three months.

Let’s take a brief look at how all these stocks perform on TipRanks’ Stock Comparison Tool:

Disclaimer & DisclosureReport an Issue

Recently, we found out about something of a potentially serious issue brewing for legacy automaker Ford F -1.68% ▼ . The United Auto Workers (UAW) union was attempting to establish a presence at the BlueOval SK plant in Kentucky, a move that would put the UAW in a position to build the next generation of vehicles. Now, the UAW is claiming victory, though some challenged ballots remain. And Ford suffered, with shares down nearly 2% in Thursday afternoon’s trading.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The reports suggest that early returns showed the UAW won the union vote at the plant, but there were two issues. One, there were a set of “contested ballots” involved, in which the vote was not so clear. Two, the vote was close to begin with. Thus, if those “contested ballots” are sufficiently swung against the UAW, the UAW could be out after all.

Reports note that the vote turned out 526 for and 515 against. However, 41 ballots are contested. The UAW asserts that the contested ballots never should have existed to begin with, cast by employees who were “…ineligible to join the bargaining unit.” No matter which side claims victory here, it will not be a big win. The vote was simply too close to be anything else.

Oh, and Another Half-Million Vehicles Recalled

It would have been remarkably depressing to issue another article about Ford recalls for the second day in a row, so I am grateful for the union update. Yes, there is another, completely separate Ford recall, and this time, around half a million vehicles are impacted.

This time, the matter relates to a ruptured hose in the brake system, which could cause brake fluid to leak. This in turn can reduce the effectiveness of brakes, lengthen stops, and potentially cause brakes to fail altogether. There are no reports of accidents, yet. The vehicles impacted are the Lincoln MKX from 2016 to 2018, and the Ford Edge from 2015 to 2018.

Is Ford Stock a Good Buy Right Now?

Turning to Wall Street, analysts have a Hold consensus rating on F stock based on three Buys, eight Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 7.2% rally in its share price over the past year, the average F price target of $10.77 per share implies 8.07% downside risk.

See more F analyst ratings

Disclosure

Disclaimer & DisclosureReport an Issue